Compare Eli Lilly And Co (LLY) vs Toronto-Dominion Bank (TD) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

TD stock trades at $120.56, down 2.46% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.74 exceeding the $1.63 estimate. Revenue growth remains steady, increasing from $56.3B in 2024 to $61.3B in 2025, while net income margin improved significantly to 33.51%.

Analyst consensus is bullish with a $153 price target representing 27% upside potential. Key risks include volatile cash flow patterns and high debt levels, while opportunities lie in continued earnings outperformance and dividend stability. The stock presents a compelling value proposition for investors seeking banking sector exposure with growth potential.